Isovitexin / HH Cancer Research Results

Isovitexin - Apigenin-6-C-Glucoside

Alternative Names: Apigenin-6-C-glucoside, apigenin-6-C-β-D-glucopyranoside

Type: Flavone C-glycoside / apigenin derivative

Function: Isovitexin is a naturally occurring C-glycosylated flavone and positional isomer of vitexin, with glucose attached to apigenin at the C-6 position. It exhibits antioxidant, anti-inflammatory, metabolic, neuroprotective, and antiproliferative activities and can influence NF-κB, Nrf2, MAPK, PI3K/AKT, AMPK, apoptotic, and oxidative-stress signaling.

Isovitexin — Isovitexin (IVT; ISV; IVX), also known as apigenin-6-C-glucoside or 6-C-β-D-glucopyranosylapigenin, is a naturally occurring C-glycosylated flavone and positional isomer of vitexin, in which glucose is attached to apigenin at carbon 6 rather than carbon 8. It occurs in food and medicinal plants including mung bean, rice, passionflower, and other botanical sources. It is formally classified as a flavone C-glycoside / apigenin derivative. Compared with vitexin, isovitexin has a smaller but distinct experimental literature and should be maintained as a separate compound. Anticancer activity remains preclinical.
-buckwheat sprouts contain orientin, isoorientin, vitexin, isovitexin, and rutin

Primary mechanisms (ranked):

1. Suppression of PI3K/AKT/mTOR survival signaling, associated with reduced proliferation, migration, invasion, EMT, and increased apoptosis.
2. Mitochondrial apoptosis through Bax induction, Bcl-2/Mcl-1 suppression, cytochrome-c release, caspase-3 activation, and PARP cleavage.
3. ER-stress-driven apoptosis and pro-death autophagy involving IRE1α/XBP1s, GRP78, CHOP, Beclin-1, ATG3/ATG5, and LC3-II.
4. Suppression of cancer stemness, including miR-34a induction and reduction of CD44, ABCG2, ALDH1, and NANOG.
5. Inhibition of EMT, migration, and invasion, substantially linked to PI3K/AKT/mTOR suppression in colorectal cancer models.
6. ROS/NRF2 modulation is strongly context-dependent: isovitexin generally decreases ROS and activates NRF2/HO-1 in nonmalignant oxidative-injury models; a generalized pro-oxidant anticancer mechanism has not been established for isovitexin.
7. Suppression of inflammatory MAPK/NF-κB signaling in nonmalignant inflammatory models.
8. CYP17A1 inhibition has recently been proposed in breast cancer, but current evidence is substantially less mature than the apoptosis and PI3K/AKT/mTOR evidence.

Bioavailability / PK relevance: Oral exposure is a significant translational limitation. C-glycosylation gives isovitexin greater chemical stability than many O-glycosides, but direct intestinal absorption is limited and substantial material reaches the intestine for microbial metabolism. Rat studies demonstrate absorption and broad tissue distribution after oral plant-extract administration, while intravenous isovitexin has a plasma half-life of approximately 1 hour and distributes particularly to kidney, intestine, and liver. Human isovitexin-specific PK data are not established.

In-vitro vs systemic exposure relevance: Many mechanistic experiments use micromolar concentrations that may be difficult to reproduce as circulating unchanged isovitexin after ordinary dietary or oral exposure. Consequently, high-concentration cell-culture findings should not be interpreted as demonstrating clinically achievable anticancer activity. Intestinal exposure and metabolites may be more pharmacologically relevant after oral administration.

Clinical evidence status: Preclinical. Anticancer evidence consists primarily of cell studies and rodent/xenograft experiments. No established human anticancer efficacy, randomized clinical trial evidence, or approved oncology indication was identified. Isovitexin has an FDA substance identifier but this does not constitute drug approval. Long-term human safety, therapeutic dosing, drug interactions, and cancer-specific pharmacokinetics remain insufficiently defined.

Mechanistic Profile

Alzheimer's disease relevance: Isovitexin has meaningful but entirely preclinical AD relevance. Direct evidence includes inhibition of AChE and BChE in biochemical assays, protection against Aβ-induced neuronal toxicity, and improvement of cognition, Aβ burden, neuroinflammation, and autophagic dysfunction in an STZ-induced mouse model. The latter study links benefit to miR-107-mediated suppression of PI3K/AKT/mTOR signaling. These findings justify retaining AD as a disease category, but they do not establish clinical efficacy.

Primary mechanisms (ranked):

1. miR-107-mediated suppression of PI3K/AKT/mTOR and restoration of autophagic regulation.
2. Reduction of experimental Aβ burden and Aβ-associated neuronal toxicity.
3. Reduction of neuroinflammation, including TNF-α, IL-6, and caspase-1 signaling.
4. AChE and BChE inhibition in biochemical assays.
5. Antioxidant/neuroprotective activity and protection from excitotoxic injury.

Clinical evidence status: Preclinical only. No human Alzheimer's disease efficacy data or validated therapeutic dosing were identified.

Alzheimer's Disease Mechanisms